Product Information
XERESE 5%-1% CREAM is a brand product labeled by Bausch Health US LLC, priced at $258.7892 per GM under NDC 00187510401. Its NADAC has been published 206 times since Nov 28, 2013.
FDA first approved this application on Jul 31, 2009.
Strength
50; 10 mg/g; mg/g
Manufacturer
Bausch Health US LLCNDC
00187510401
Classification
Brand
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/17/2025
Active Ingredients
ACYCLOVIR; HYDROCORTISONEApproval Type
New Drug (NDA)
FDA Application
NDA022436FDA Approved
7/31/2009
On Market Since
7/31/2009
Pharmacological Classes
Price Statistics
The NADAC for XERESE 5%-1% CREAM has been published 206 times since Nov 28, 2013, and over the history we have for it it has risen 312.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $258.7892 per GM |
|---|---|
| All-time high | $258.7892 (Oct 1, 2025) |
| All-time low | $62.7062 (Nov 28, 2013) |
| Median price | $199.5752 |
| Average price | $175.9914 |
| Largest weekly change | +30.0% (Jun 11, 2014) |
| Weeks tracked | 206 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+29.7%
5Y
+29.7%
All
+312.7%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Acyclovir and Hydrocortisone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch Health US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acyclovir and Hydrocortisone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XERESE 5%-1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for XERESE 5%-1% CREAM, manufactured by Bausch Health US LLC, is $258.7892 per GM (NDC 00187510401), effective Oct 1, 2025.
How has the price of XERESE 5%-1% CREAM changed over time?
Over the history we have for it, the NADAC for XERESE 5%-1% CREAM has risen 312.7%. It has been tracked across 206 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for XERESE 5%-1% CREAM?
Since Nov 28, 2013, the NADAC for XERESE 5%-1% CREAM has ranged from a low of $62.7062 (Nov 28, 2013) to a high of $258.7892 (Oct 1, 2025), with a median of $199.5752 per GM.
Are there cheaper alternatives to XERESE 5%-1% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of XERESE 5%-1% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XERESE 5%-1% CREAM?
XERESE 5%-1% CREAM (NDC 00187510401) is labeled by Bausch Health US LLC, and CMS classifies it as a brand product.